Welcome to our dedicated page for Onco-Innovations news (Ticker: ONNVF), a resource for investors and traders seeking the latest updates and insights on Onco-Innovations stock.
News for Onco-Innovations Limited (ONNVF) centers on its activities in oncology research, preclinical drug development, AI-enabled precision medicine, and corporate financing. The company describes itself as a Canadian-based oncology-focused organization with an exclusive worldwide license to patented technology targeting solid tumours, including its PNKP Inhibitor Technology platform.
Investors and observers following Onco-Innovations’ news can expect updates on the advancement of its PNKP Inhibitor Technology (A83B4C63), including manufacturing milestones with Dalton Pharma Services such as process optimization, intermediate scale-up, analytical method development, and preparation for potential future clinical material production. Releases also cover collaborations with partners like Kuano Ltd., where quantum-ready molecular modelling and AI-driven compound design are being applied to deepen understanding of PNKP inhibition and guide next-generation therapeutic candidates.
Another important stream of news involves Onco-Innovations’ subsidiary Inka Health and its SynoGraph platform. Announcements have highlighted publications on the transportability of real-world evidence, integration of advanced statistical methods into SynoGraph, and participation in precision oncology forums with organizations such as Colorectal Cancer Canada. These items illustrate how the company links AI, real-world data, and oncology decision-making.
Corporate and capital markets developments also feature in the news flow. Onco-Innovations has reported private placements, board appointments, marketing engagements, and its intention to pursue a potential Nasdaq cross-listing with the support of a U.S. investment bank. For a consolidated view of these scientific, strategic, and financing updates, this news page provides a single location to review the company’s disclosed developments over time.
Onco-Innovations (OTCQB:ONNVF) announced initiation of analytical method validation for A83B4C63, the API for its PNKP inhibitor ONC010. The work with Dalton Pharma Services aims to build a robust CMC control strategy aligned with ICH guidelines to support IND-enabling studies and future Phase I trials.
Onco-Innovations (OTCQB:ONNVF) announced a research collaboration between its subsidiary Inka Health and AstraZeneca within the PROmAI program (Predicting Oncology Outcomes using Multimodal Artificial Intelligence).
The project focuses on AI-based multimodal and causal methods to better predict oncology clinical outcomes, understand patient heterogeneity, and inform future oncology research and development.
Onco-Innovations (OTCQB:ONNVF) announced that Nucro-Technics has begun advanced bioanalytical LC-MS method development and non-GLP analyses to measure A83B4C63, the API for its exclusively licensed PNKP Inhibitor Technology.
This work supports ongoing non-GLP PK and biodistribution animal studies, aims to generate exposure and distribution datasets, and advances the Company toward IND-enabling activities.
Onco-Innovations (OTCQB:ONNVF) announced that its wholly owned subsidiary, Inka Health, has started a collaborative research agreement with GSK to develop real-world data methodologies for improving the transportability of oncology clinical trial results.
The Project will include literature review, a structured evaluation framework, retrospective validation using public oncology datasets, and joint scientific manuscripts. Work leverages Inka Health's advanced analytics and GSK epidemiology and RWE expertise.
Onco-Innovations (OTCQB:ONNVF) advanced CMC scale-up with Dalton Pharma Services, increasing precursor A83 production to 1,560 g and initiating a 2 kg non‑GMP synthesis of API A83B4C63 to support IND‑enabling studies and Phase I readiness. Activities include stability, analytical characterization aligned with ICH, and pilot‑scale process development at Dalton's FDA‑registered, Health Canada‑approved Toronto facility. The company also extended a market‑awareness engagement with MCS for a cash fee of €210,000 and obtained a returned unused balance of US$269,688 to allocate toward that fee.
Onco-Innovations (OTCQB:ONNVF) announced the successful scale-up of intermediates A83 and B4, advancing CMC work for its nanoparticle PNKP inhibitor drug candidate ONC010. The program moved both intermediates from lab-scale to intermediate-scale with Dalton Pharma Services, supporting IND-enabling activities and future GMP manufacturing.
Ongoing work includes integrated API synthesis, analytical method development, polymer platform scale-up, preclinical studies, and clinical planning to position ONC010 for first-in-human trials.
Onco-Innovations (OTCQB:ONNVF) advanced an analytical method — refractive index detection with gel permeation chromatography (RI-GPC) — to characterize a key polymer in its PNKP Inhibitor Technology. The polymer forms the nanoparticle micelle delivery system for lead candidate ONC010. The qualification aims to improve polymer molecular-weight control, support formulation reproducibility, enable manufacturing scale-up, and strengthen the CMC package ahead of IND-enabling studies and planned Phase 1 activities.
Onco-Innovations (OTCQB:ONNVF) announced completion of analytical method development for its monomer intermediate supporting ONC010. A robust RP-HPLC method was developed and pre-validated with high sensitivity, linearity, and consistent chromatographic behavior to support impurity detection, quality control and future GMP activities.
Process development yielded intermediary scale batches of ~20 g and ~181 g, each confirmed at not less than 98% purity by HPLC; the method will form the basis for formal CMC analytical procedures as the company advances toward IND-enabling work.
Onco-Innovations (OTCQB:ONNVF) appointed Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development effective April 17, 2026. The hires aim to advance the company's PNKP Inhibitor Technology (ONC010) through IND-enabling activities toward first-in-human studies and improve regulatory and CMC readiness.
The board also approved issuance of 1,360,000 RSUs, and the company's preliminary base shelf prospectus remains under review by the Alberta Securities Commission.
Onco-Innovations (OTCQB:ONNVF) executed an engagement agreement with RDI Partners and formed Onco-Innovations AU Pty. Ltd. to support planned Phase I development in Australia. The company also engaged MCS for digital marketing services and paid EUR 213,000 for services through July 30, 2026.
The initiatives aim to position potential eligibility for Australia’s 43.5% R&D Tax Incentive, prepare HREC submission, follow TGA CTN pathway, and strengthen governance and financial oversight for clinical activation.